

Restated Rules

- **Budget Discipline:** No additional capital beyond the current portfolio value is allowed. All trades must be funded from existing cash (\$0.85) or by selling current holdings. Cash usage will be tracked precisely to maintain the hard budget limit.
- **Trade Restrictions:** Only long positions in U.S. micro-cap stocks (market capitalization < **\$300 million**) are permitted. No use of options, short selling, leverage, margin, or any derivatives – strictly cash equity trades in full share increments.
- **Micro-cap Universe Compliance:** Before adding to or initiating any position, confirm the stock's market cap is under \$300M at the last close. (All current holdings remain below this threshold: MIST ~\$273M ¹ ; VTGN ~\$190M ² ; SLS ~\$231M ³ .) If a holding's value grows above \$300M, it can be held or sold, but not added to.
- **Liquidity & Execution:** Focus on liquid micro-caps with sufficient trading volume to handle our order sizes with minimal slippage. All orders will be placed in full shares only, using limit orders (DAY by default) unless a market order is justified (e.g. urgent exit). No trade should represent a significant portion of the stock's average daily volume to avoid moving the market.
- **Risk Control:** Every position must have a stop-loss level as specified. Respect these stops and position sizing guidelines to limit downside risk. Any breach of stop-loss or oversizing is not allowed; if identified, it will be addressed immediately.
- **Trading Cadence:** This is the weekly deep-research window (Week 24) for portfolio review and strategy update. We have full discretion to keep, add, trim, or exit positions, and to initiate new positions if warranted. However, outside of this window, only pre-planned stop-loss or take-profit orders will execute.
- **Objective:** Optimize risk-adjusted returns under the above constraints. We are free to make any portfolio changes deemed in our best interest to generate alpha, provided they comply with all rules. The emphasis is on prudent management and catalyst-driven opportunities to maximize performance in the final weeks of the experiment.

Research Scope

For this week's deep-dive, we performed a comprehensive review of each current holding's latest developments, checked for any new fundamental or technical signals, and scoured the micro-cap universe for any fresh catalyst-driven opportunities:

- **Current Holdings Update:** We reviewed recent news, press releases, and price action for Milestone (MIST), VistaGen (VTGN), and SELLAS (SLS). This included confirming upcoming catalyst dates and any changes in guidance or financial conditions. For example, we verified MIST's FDA decision (PDUFA) remains set for December 13, 2025 ⁴ and noted that MIST's market cap is ~\$273M at the current price ¹ . We also reviewed VistaGen's latest earnings update, which **reaffirmed that PALISADE-3 Phase 3 trial results are on track for release by end of 2025 and that an NDA filing is targeted around mid-2026 if data are positive** ⁵ , indicating management's confidence. For SLS, we examined their Q3 update: the Phase 3 REGAL trial final analysis is expected by year-end (event-driven) and the interim Data Monitoring Committee (IDMC) in August gave a positive

recommendation to continue unmodified ⁶. We also confirmed SELLAS bolstered its cash position (>\$73M pro forma after warrant exercises) to fund operations well into 2026 ⁷ – an important risk mitigator for a small biotech. Technical charts for each stock were checked to assess price trends: all three have been in uptrends over the past month, reflecting growing investor anticipation as the catalysts near. No abnormal trading patterns (like insider selling or unusual volume without news) were observed that would undermine our theses.

- **New Candidate Search:** We scanned for other U.S. micro-cap stocks with imminent catalysts (e.g. FDA approvals or trial readouts in December 2025) to see if any could outperform our current holdings. We identified a few biotech catalysts in December, but most involve larger companies outside our market cap limit – for instance, Agios (AGIO) has a Dec 7 PDUFA and BioCryst (BCRX) a Dec 12 PDUFA, but their market caps (~\$1.7B ⁸ and ~\$1.5B ⁹ respectively) far exceed our \$300M ceiling. Within the micro-cap space, we noted **Aspire Biopharma (ASBP)**, a tiny ~\$10M biotech, aiming for an FDA submission of its sublingual aspirin product by end of 2025 ¹⁰. However, an NDA *submission* (as opposed to an approval decision or pivotal trial result) is a relatively mild catalyst, and ASBP's recent 90%+ stock plunge (to ~\$0.10/share ¹¹) and extremely low market cap signal very high risk – it lacks the near-term transformative event or stability we need. We found no other micro-cap with a **definitive, near-term binary catalyst** as compelling as the ones our portfolio already targets.

- **Validation of Constraints:** As part of our research, we double-checked that any prospective trade would comply with our rules. All current holdings are under \$300M market cap (as cited above) and sufficiently liquid. For any potential new ticker, we verified market cap and typical volume. We also updated our knowledge on execution mechanics: by default, we will use **limit DAY orders** placed at the next market open for any buys or sells (since no specific alternative was given). This means orders will try to fill at our limit price (or better) during the day, and expire end-of-day if not filled. If an order is critical (like a stop-loss triggering), we may use **market orders** to ensure execution, but only with clear reasoning (e.g. reacting to an FDA decision outcome). All planned orders in this report assume standard execution at the next trading session unless stated otherwise.

In summary, our research confirms that our current biotech positions still represent the best high-upside opportunities for the final weeks. We did not find a clearly superior candidate that would justify swapping out any existing holding (especially given we have essentially no free cash). The focus now shifts to fine-tuning our positions (stops, etc.), and preparing execution plans around the imminent catalyst events.

Current Portfolio Assessment

Below is an updated assessment of each holding, including its role in the portfolio, entry point, cost basis, current stop-loss, our conviction level, and current status:

Ticker	Role / Thesis	Entry Date	Avg. Cost	Current Stop	Conviction	Status
MIST (Milestone Pharmaceuticals)	FDA approval catalyst play (etripamil nasal spray for PSVT). PDUFA date Dec 13, 2025 expected ⁴ . We anticipate FDA approval given strong Phase 3 data and resolved manufacturing issues.	Oct 2025 (est.)	\$1.75	\$1.60 (stop-loss)	High – Very favorable risk/reward; high probability of approval and significant upside (analyst PT ~\$6+) if approved.	Hold through FDA decision; will sell into strength on approval or cut loss if rejection (stop in place).
VTGN (VistaGen Therapeutics)	Phase 3 trial catalyst (PALISADE-3 for social anxiety disorder). Top-line data due by end of Q4 2025 ⁵ . Thesis: redesigned trial has a good chance to succeed, which could re-rate the stock sharply upward.	Nov 2025 (est.)	\$4.01	\$3.20 (stop-loss)	High – We are optimistic due to improved trial design and management's confidence (NDA targeted mid-2026 on success ⁵). Upside could be +100% or more on positive data.	Hold through trial readout; stop-loss set to limit downside. Prepared to take profit if data are positive (expected in ~3-4 weeks).

Ticker	Role / Thesis	Entry Date	Avg. Cost	Current Stop	Conviction	Status
SLS (SELLAS Life Sciences)	Phase 3 trial catalyst (REGAL final survival analysis in AML). Data anticipated ~year-end 2025 (event-driven) ⁶ . High-risk “lottery ticket” play: success could multi-bag, failure could tank.	Nov 2025 (est.)	\$1.41	\$1.10 (stop-loss)	Moderate – Science is promising but outcome is uncertain (novel cancer vaccine). Conviction is tempered by risk, hence our smallest position. Notably, an IDMC gave a positive go-ahead in Aug ⁶ and the company’s strong cash ~\$73M ⁷ means even if trial fails, the stock might retain some value (not a zero).	Hold through data; sized smaller due to risk. Stop-loss in place to contain a negative outcome. Will capitalize on any major spike if results are positive.

Notes: We adjusted MIST’s stop-loss to \$1.60 (from the initial \$1.50) last week to lock in at least breakeven on that position, given the stock’s rise to the \$2.60+ area. VTGN and SLS stops remain at \$3.20 and \$1.10 respectively, which we deem appropriate to give these volatile stocks room **but** still protect us from worst-case collapses. Conviction levels reflect our qualitative assessment of probability-weighted upside. All three positions are in the biotech sector but target completely different indications (cardiovascular, CNS, oncology), providing event diversification. The portfolio is concentrated by design – we have **no “low conviction” filler positions**, only high-upside bets that align with our goal of catching up to the benchmark in the final weeks. Current allocation is roughly 42% MIST, 33% VTGN, 25% SLS by value, which we are comfortable with given our theses.

Candidate Set

After evaluating potential additions, we have decided **not** to introduce any new positions this week. Below we list the main candidates we considered and why none were ultimately added:

- **AGIO** – *Agios Pharmaceuticals*. **Catalyst:** FDA decision on pyridoxal phosphate analog (Agios’ metabolic drug) on Dec 7, 2025. **Thesis:** Could rally on approval. **Liquidity:** High. **Note:** **Excluded** due to market cap ~\$1.7B ⁸ (well above micro-cap limit). Agios is not eligible for our portfolio rules despite the upcoming catalyst.

- **BCRX** – *BioCryst Pharmaceuticals*. **Catalyst:** FDA decision for BCX10013 (oral Factor D inhibitor) on Dec 12, 2025. **Thesis:** Significant event; success could boost shares. **Liquidity:** High. **Note: Excluded** – market cap ~\$1.5B ⁹, above our \$300M cap limit.
- **ASBP** – *Aspire Biopharma*. **Catalyst:** Targeting an **FDA submission** (not approval) for Fast-Onset Aspirin (acute use) in H2 2025 ¹⁰ – likely by end of December. Also developing a needle-free semaglutide (early stage). **Thesis:** Highly speculative; if the NDA filing happens or if any partnership news emerges, the stock (recently collapsed to ~\$0.10) could rebound. **Liquidity:** Moderate (trades millions of shares, but at very low price). **Note:** We **decided against initiating** ASBP. Its market cap is extremely low (~\$5–11M) ¹², reflecting distress – indeed the stock fell ~90% in the past month. An NDA submission alone may not be enough to move the needle, and the company likely faces financing/dilution risk. In short, while the upside of a turnaround is huge in theory, the probability and timing are too uncertain for the last few weeks of our experiment.
- **Other Micro-caps:** We screened for any other biotech or tech micro-caps with near-term binary events (late Q4 2025). No compelling opportunities surfaced that fit our criteria. Many micro-cap biotechs have timelines beyond December or catalysts that are incremental. We prefer catalysts that will play out within our remaining horizon. Outside biotech, we considered whether to play any beaten-down micro-cap with a potential year-end bounce, but without a clear catalyst, that would be a pure speculation. Given our lack of spare cash (only \$0.85 free) and the high conviction in our current positions, adding any new position would require us to sell or trim something – and none of our holdings merit replacement at this point.

Conclusion on Candidates: We will **stand pat** with the current trio. MIST, VTGN, and SLS each have imminent, independent catalysts with asymmetric upside. No alternative presented a clearly superior risk-reward profile for the next few weeks. It is better to concentrate our firepower on these known events rather than dilute the portfolio with a new name lacking an immediate catalyst or to prematurely take profits from a current holding to fund a new bet. We'll of course remain alert during the week in case an unexpected opportunity (or a problem with our theses) arises, but as of now, the best course is to maintain our positions and focus on execution.

Portfolio Actions

Based on the above analysis, here are our decisions for each current holding and any potential adjustments:

- **Keep MIST – No Change to Position Size:** Milestone Pharmaceuticals will be maintained at 14 shares. **Reason:** The FDA approval catalyst on 12/13/2025 is the highest-confidence event in our portfolio. All research reinforces that approval is likely (robust data, prior manufacturing issues resolved, company prepared with financing) and that upside could be significant (potential stock jump into the \$3–4+ range on news). We want full exposure to this outcome. We are not trimming because we don't want to cap our upside; we've waited for this moment and our thesis remains strong. Only action is ensuring our stop-loss is appropriately set (see Orders) to guard against a surprise rejection. Otherwise, full steam ahead through the decision.

- **Keep VTGN – No Change to Position Size:** VistaGen Therapeutics (6 shares) will also be held as is. **Reason:** The imminent Phase 3 readout for fasedienol could be a game-changer. Our conviction is bolstered by management’s recent affirmation that they expect data by year-end and are already eyeing an NDA mid-next-year if positive ⁵. The stock has been trending up (now ~\$4.90) which suggests growing optimism, but it’s still far below where it could trade on successful results (we estimate it could double or more given the prior skepticism around this program). We are not taking profits here either, as the main move (if any) is yet to come. The stop-loss at \$3.20 stays in place to limit damage if the trial disappoints. No adds either – while we’d love to have more VTGN, we have no cash unless we cut something else, which we won’t do pre-catalyst. So we simply maintain our position and game plan (hold through data, then react swiftly).
- **Keep SLS – No Change to Position Size:** SELLAS Life Sciences (13 shares) remains in the portfolio. **Reason:** SLS is admittedly the highest risk of our trio, but also carries extremely high reward potential. We sized it smaller originally for this reason, and that sizing (about 25% allocation) still feels right. The REGAL Phase 3 could read out any day in the coming weeks. If positive, SLS could rally multiple times over (perhaps toward \$5 as speculated earlier); if negative, the stock will likely crater (perhaps <\$1). We have a **tight stop at \$1.10** to automatically cap our downside. We debated whether to *trim or sell SLS* before data given its binary nature and the fact that it has modestly appreciated (~15%) since our entry – essentially, do we “take chips off” this high-risk bet? In the end, we’ll **keep the full position** because (a) its notional size is small enough that even a total loss won’t kill the portfolio, and (b) selling now would forfeit the chance at a big payoff which we arguably need. Our research did not uncover any red flags to make us bail early – on the contrary, the company’s cash infusion and the IDMC’s prior go-ahead give us some confidence to ride this out. Thus, no trimming; we’ll let the catalyst play out.
- **No Exits at This Time:** We are not exiting any positions this week. All three holdings are marching toward their critical catalysts. Exiting now would mean giving up the very outcomes we’ve positioned for. Unless new negative information emerges *before* the events (which we will monitor closely), we intend to see each catalyst through. We have contingency plans (stops, etc.) for the downside scenarios, which allows us to stay in the game without reckless risk.
- **No New Initiations:** As discussed in the Candidate Set, we are not initiating any new positions. With effectively zero spare cash, adding a new stock would require sacrificing part of an existing position – an unwarranted move given our high convictions. Moreover, no other micro-cap catalyst matches the timing and upside profile of what we already hold. It’s more prudent to concentrate on executing our current strategy well, rather than to introduce a new variable at the last minute.

In summary, our **portfolio actions are to hold steady on all current positions**, making only minor tactical adjustments (e.g. updating stop orders) rather than major re-allocations. We believe the portfolio is optimally positioned for the upcoming week’s events.

Exact Orders

Given the decision to maintain all holdings, our trades this week consist mainly of **order updates (stop-loss adjustments)** and no new buy/sell initiations. Below are the exact orders we will place at the market open on Monday (2025-12-01), with details:

Action	Ticker	Shares	Order Type	Limit/ Stop Price	Time in Force	Execution Date	Stop-Loss (if Buy)	Special Instructions / Rationale
Modify Stop (Sell)	MIST	14	Stop (GTC) – modify	\$1.60 (stop price)	GTC	2025-12-01 (modify existing)	–	<i>Raise stop-loss from \$1.50 to \$1.60. This locks in at least breakeven on MIST and protects a portion of our gains, while still giving the stock ample room before the FDA decision. (If an adverse outcome occurs, the stock may gap below \$1.60, but this stop could catch any partial information sell-off or a mild delay scenario.)</i>
Confirm Stop (No change)	VTGN	6	Stop (GTC) – confirm	\$3.20 (stop price)	GTC	– (existing)	–	<i>No change to VTGN's stop-loss. We reconfirm the GTC sell-stop at \$3.20 remains active. This level is about 20% below our cost, chosen to avoid getting whipsawed by normal volatility but to trigger if the trial result (or other news) is decisively negative.</i>

Action	Ticker	Shares	Order Type	Limit/ Stop Price	Time in Force	Execution Date	Stop-Loss (if Buy)	Special Instructions / Rationale
Confirm Stop (No change)	SLS	13	Stop (GTC) – confirm	\$1.10 (stop price)	GTC	– (existing)	–	<i>No change to SLS's stop-loss. The GTC stop at \$1.10 stays in place. This is a tight stop (~32% below current price) reflecting SLS's risk – it's set just below the trading range of the past months, to activate on a clear breakdown (likely on trial failure news).</i>

Notes on Orders: All stop orders are **sell stop** orders. They will convert to market orders if triggered, meaning if the stock trades at or below the stop price, our shares will be sold at the next available price. We prefer GTC stops (Good-Till-Cancelled) so they remain in effect through the catalyst windows. The MIST stop modification will be effective from Monday onwards, replacing the prior \$1.50 stop with \$1.60. (We set this slightly below a recent support level and well below the current ~\$2.70 price, balancing risk protection with avoiding premature trigger.) For VTGN and SLS, we are simply leaving the existing stop orders as-is (no need to re-enter them; we just confirm that they're active and at the intended levels).

No **limit sell** orders are being placed for profit-taking at this time – we will manage exits around the catalysts manually (or via stops) rather than pre-setting a sell limit, because we want flexibility to capture as much upside as possible. For example, if MIST is approved, it could spike well beyond any conservative limit price we might set, so we plan to execute that dynamically (see Monitoring Plan). Likewise for SLS and VTGN on positive news, we'll likely sell into strength in stages rather than all-or-nothing with a preset limit; thus no limit orders for those are entered now. We also are not placing any **buy orders** for new positions this week, given our decision to hold our current names and lack of cash.

If any order does execute, we will update our cash and holdings accordingly. As of now, these orders mostly serve as contingency measures (stops) to enforce our risk discipline automatically.

Risk And Liquidity Checks

We have reviewed the portfolio's post-trade risk profile and liquidity considerations to ensure compliance and prudence:

- **Portfolio Concentration (after trades):** The portfolio remains concentrated in three positions – approximately 42% in MIST, 33% in VTGN, 25% in SLS by current value. No single position exceeds 50% of the portfolio, so there's no breach of a concentration limit (none was explicitly given, but we note this for risk awareness). The concentration is intentional, given each holding's high conviction catalyst. We acknowledge this is an aggressive stance (minimal diversification), but it aligns with our end-game strategy to seek outsized gains. We are comfortable with the concentration *given the independent nature of the catalysts*: a setback in one should not directly affect the outcome of the others (for instance, a trial failure in oncology shouldn't impact a cardiac drug FDA decision, etc.). We have also sized them according to conviction and risk (smaller size for the riskiest SLS).
- **Cash After Trades:** The cash balance will remain **\$0.85** after placing the above orders, assuming none execute immediately. We are not deploying any cash this week. This tiny cash reserve is effectively just a residual amount – for all intents and purposes, we are fully invested. If one of our stop-loss orders triggers (or we sell a position on good news), that would raise cash, and we would then decide how to redeploy. For now, \$0.85 cash is essentially an idle buffer to cover any minor fees or slippage. We note that we have adhered to the hard budget: no new capital has been added at any point.
- **Stop-Loss and Order Sizes vs. Liquidity:** All our positions and planned trades are very small relative to market volumes, ensuring ease of execution:
 - **MIST:** 14 shares. Average daily volume is in the millions (e.g., ~3.3M shares on Nov 28 ¹³). Our sale of 14 shares – whether via stop or manual sell – is <0.001% of a typical day's volume (practically invisible in the order flow). We anticipate no liquidity issues or meaningful slippage; even a market order would execute near the quoted price.
 - **VTGN:** 6 shares. VTGN's recent daily volume has been ~0.5M–1M shares ¹⁴. Our 6-share exit (if it occurs) is an infinitesimal fraction of that (<0.002% of daily volume). Liquidity is more than sufficient.
 - **SLS:** 13 shares. SLS trades around 2–3 million shares per day on average ¹⁵. Our 13 shares are ~0.0006% of a day's volume – again negligible. No liquidity concerns here.
 - **Order Types:** We are mostly using stop orders which, when triggered, execute at market. Given the deep liquidity relative to our size, we expect minimal slippage on stops. (The bigger risk is price gapping on news, but that's not a liquidity issue – it's event risk, which our stops can't fully mitigate if an overnight gap occurs. We accept that and rely on having sized positions appropriately.)
- **Bid/Ask Spreads:** All three stocks have tight bid-ask spreads for micro-caps (usually a few cents) due to decent volume and interest, so transacting in our small quantities should happen at fair prices.
- **Stop-Loss Placement Logic:** We double-checked that our stop levels make sense technically and fundamentally:

- MIST \$1.60 is ~7% below our cost and about 40% below the current price – a **disaster stop** primarily. It's below any minor support levels, meaning it should only trigger on a substantial negative event. It balances risk (we won't round-trip a gain into a big loss) with the need to avoid being stopped on normal volatility (MIST hasn't traded near \$1.60 since early November).
- VTGN \$3.20 is about 20% below cost and ~35% below current price. It is around the area the stock consolidated after its fall 2022 reverse split (converted price). Essentially, if VTGN falls back to the low-\$3s, it likely means the market is either anticipating bad news or reacting to it – so we'd want out. This stop is wide enough that random 5-10% swings won't trigger it.
- SLS \$1.10 is just below SLS's multi-month support in the \$1.20-\$1.30 range. We set it tight because SLS could implode on trial failure – in which case, any stop might not help much – but also because if the stock starts slipping toward \$1.10 on no news, that could indicate leakage or pessimism where we might choose to step aside. It's a bit above the likely post-failure price (maybe \$0.50-\$0.70), so it might catch some value on a bad outcome. On a good outcome, obviously the stop won't be reached.
- **Risk of Gap Moves:** Acknowledging risk control, stops are in place, but biotech catalysts can cause overnight gaps where stops fall far from their set prices. We accept this risk – it's inherent in our strategy. We've mitigated by position sizing: even if SLS gaps to \$0.50 (worst case), that ~70% loss on a 25% position is about a 17.5% hit to the portfolio – painful but not a wipeout. Similar math for VTGN (could gap down 50% or more on failure; our 33% position might cost ~16% of portfolio). These are the risks we deliberately shoulder in pursuit of a potential 50-100% portfolio gain if one or more catalysts hit. So the **downside** in worst case (all three fail and gap down hugely) is largely capped by stops/position sizes – we'd lose perhaps half the portfolio (our max drawdown to date is ~50% **【user data】** , reflecting earlier declines). The **upside** of even one success could be +20-30% or more to portfolio, and multiple successes could compound that.

In summary, our risk controls are in place and we are in compliance with all constraints. Liquidity is not a concern for executing our plans. The portfolio is concentrated and volatile by design, but all moves have been carefully weighed. We will monitor risk metrics (like drawdown) but at this point our strategy intentionally tolerates higher volatility in exchange for potential large gains. No risk limit (such as max drawdown or beta constraint) has been violated given the special situation nature of this experiment.

Monitoring Plan

The coming week (Week 24) is critical, with at least one major catalyst likely to occur. Our monitoring and execution plan is as follows:

1. **Monitor SLS (REGAL Phase 3 outcome in AML):** This readout is event-driven and could hit at any time (the company guided “by year-end” ⁶). We will **check news daily, pre-market and throughout each trading day** for any press release from SELLAS or major media reporting the trial result. If news drops:
2. If **positive** (trial meets endpoint): Expect a sharp rally. We plan to **sell into strength the same day**. Specifically, we might stagger sell orders to optimize exit price (e.g. sell part of the position on the initial spike and part later if momentum continues). We will likely target an average exit in the \$3-\$5 range (depending on how high it jumps – those levels would secure a multi-bagger gain). Because

we cannot place orders outside the weekly window here in the report, this will be executed manually in real-time. We will update our next report with exactly how we traded it.

3. If **negative** (trial fails or inconclusive): Our stop-loss at \$1.10 should trigger. We will monitor its execution. If the news comes outside trading hours and the stock opens significantly below \$1.10, we may get a bad fill; we'll still take the exit (no attempt to "hope for a rebound" – the thesis would be busted). We'll log the realized exit price and reallocate remaining capital accordingly next week.
4. In either case, **volatility will be high**. We will be watching Level II quotes and news feeds (e.g., Bloomberg, company IR site, Twitter) for secondary details. No matter the outcome, we will remove the stop once the news is out (to avoid it firing during wild swings if we're manually managing the trade).
5. Also note: SLS has an ASH conference presentation for their other program on Dec 6-9 ¹⁶. We'll listen for any read-across (though main stock driver is REGAL). If the REGAL result hasn't come by then, any hints or tone from management at ASH will be noted.
6. **Monitor MIST (FDA PDUFA on Dec 13, 2025)**: We are entering the FDA decision window.
7. We will **monitor FDA news announcements and Milestone's press releases** closely around Dec 13. Often, FDA approvals/CRLs can hit after market close on the PDUFA date or sometimes early. We'll be vigilant on Dec 12-13 in particular. We have the luxury that by the time MIST's event happens, we should know SLS's outcome and possibly VTGN's, so our focus can shift.
8. If **approval news** comes: MIST could gap up significantly. We will likely execute a **market sell near the open following the news** (because in a fast market, a limit might miss the peak – we prefer execution certainty). Alternatively, if news comes intraday, we'll watch the price action; we might sell half on the initial spike and let the rest ride with a trailing stop to catch further upside if the market enthusiasm sustains. We plan to **secure profits** on the approval day because small-cap biotechs often fade after the initial euphoria. We anticipate selling most or all of our 14 shares in the mid-\$3s or higher (our thesis suggests ~\$3.50-\$4.00+ is attainable on approval). We'll not hold too long after news – maybe keep a token share or two if we see longer-term value, but likely we'll realize gains to ensure a strong finish for the portfolio.
9. If **negative news (CRL)**: The stock will likely crater (possibly 50%+ drop). Our stop \$1.60 will trigger, but as noted, a gap might mean an actual exit around ~\$1.00 or wherever it opens. We will monitor pre-market trading on Dec 14 (if news is after-hours on the 13th) to gauge where we might fill. If the stop doesn't trigger for some reason (e.g., stock is halted and then reopens below stop), we'll quickly enter a market sell to close the position. Essentially, in a failure scenario, we cut our losses immediately and salvage capital. We'll then reassess how to deploy any remaining funds (perhaps into VTGN if its catalyst is still pending and thesis intact).
10. **No matter what, we will adjust** our stop-loss on MIST upwards once we're very close to the decision (likely turning it into a tighter trailing stop on Dec 12) to protect gains in case of any last-minute rumors or volatility. This will be managed manually.
11. We'll also be watching broader FDA updates (sometimes there are FDA delay announcements or advisory committee outcomes that can be foreshadowing).
12. **Monitor VTGN (Phase 3 social anxiety trial)**: The top-line data is expected by *end of Q4*, which could mean late December.

13. We will monitor **VistaGen's press releases and filings** – since they said by year-end, this could fall in Week 25 or 26. It's possible the readout comes around Christmas week. We have to be prepared that it might even slip to the final week of December (our experiment end). We'll stay alert daily from mid-December onward.
14. If **positive data**: Expect a big jump (the stock could easily move +50-100% given how transformative success would be for a company that had a prior failure). We will likely **sell in stages** to maximize our exit price. For example, if it pops from ~\$5 to \$8-\$10, we might sell half immediately around those levels (locking in a solid gain), and let the rest run a bit in case of follow-through buying or a short squeeze. We'll use tight stops on any remaining shares after the initial surge. Our goal will be to ensure we capture the win. Since this event might occur near the very end, we'll coordinate trades to make sure they happen before the experiment concludes on 12/27.
15. If **negative data**: The stop at \$3.20 is our safeguard. We'll be watching pre-market if the PR comes before open. A bad result likely sends VTGN back toward \$2 or even lower (remember it was a penny stock pre-reverse-split). We'll let the stop sell our shares around \$3.20 (or whatever the market will bear). After that, we'll likely not re-enter VistaGen; the thesis would be broken. We'd allocate whatever cash is recovered to the remaining catalyst (if any) or just hold cash if it's very late.
16. **Partial readouts or delays**: If by mid-December we haven't heard anything, we'll listen to any communication from the company – if they unexpectedly delay data release (which would be viewed negatively by the market), we might consider exiting or at least tightening the stop further, because any deviation from "data by end of year" would shake confidence. Also, we'll keep an eye on competitor news (though VistaGen's drug is quite unique).
17. One more nuance: VistaGen has another trial (PALISADE-4) reading out H1 2026. If PALISADE-3 fails, they might still continue the other – but that won't help our timeframe, so we likely wouldn't stick around just for that.
18. **General Market and Other Monitoring**: While our focus is on specific catalysts, we'll keep an eye on macro or sector news that could impact our positions:
19. Any FDA communications or broader biotech sentiment (e.g., if the FDA starts issuing negative decisions broadly, it could temper expectations).
20. Overall market volatility (though our stocks have low correlation to S&P, a big risk-off move could affect small caps short-term).
21. We will also monitor **trading volumes and price action** in the days leading up to each catalyst. Unusual moves could indicate insider sentiment (for example, if SLS skyrockets on no news, it might hint something leaked positively – we'd still likely hold, but might consider trimming a bit into an unexplained rally to de-risk).
22. Since two of our events are binary, we're mostly at the mercy of news, but any clues or early indicators (forum chatter, etc.) will be noted, albeit skeptically.

In summary, the plan is to **stay extremely vigilant** on news for SLS, MIST, and VTGN. We have stops as safety nets, but we prefer to actively manage the positions around news to maximize outcomes. This means being ready to execute trades during the week as needed: - If things go right, actively lock in gains. - If things go wrong, ensure exits are swift. - If opportunities to reallocate arise (e.g., one catalyst wins big and we suddenly have a lot more cash before the next event), we'll adjust on the fly (potentially increasing the remaining positions or adding a new one if time permits). Those decisions will be documented in the next weekly report.

Thesis Review Summary

As we head into Week 24, our portfolio remains an all-or-nothing biotech catalyst play. Below is a brief recap of each position's thesis, recent developments, and our confidence level, which reinforces why we are sticking to this strategy:

- **Milestone Pharmaceuticals (MIST)** – *Thesis:* MIST's nasal spray (etripamil) for PSVT has a high likelihood of FDA approval on Dec 13. The Phase 3 efficacy was strong (significantly higher conversion to normal heart rhythm vs placebo), and manufacturing issues from the prior CRL have been resolved ¹⁷. The company's tone is optimistic, and importantly they secured non-dilutive funding (a \$75M milestone payment upon approval) which means they can launch without an imminent cash crunch ¹⁸. **Recent Update:** The stock has climbed into the high-\$2s as the decision nears, indicating investor anticipation. No negative signals emerged in our research – if anything, the Q3 update bolstered confidence (management “excited” for the PDUFA). **Catalyst Outlook:** We are *highly confident* in approval. The unmet need (at-home PSVT treatment) and clean data support it. Upside: we estimate the stock could trade in the \$3.50–\$4.50 range on approval news (analysts' average target is \$6+ ¹⁹, but we'd be prudent in expectations). Downside: a rejection would likely halve the stock or worse; however, our stop and MIST's ~\$1.50/share cash on hand provides some backstop value. **Plan:** Hold through the decision. If approval, sell most/all into the post-news rally (locking in what would be roughly a +100% gain from our entry). If a surprise rejection, rely on stop to exit and preserve capital. **Thesis Confidence:** Very high – this is our top play, and we feel the risk/reward is in our favor.
- **VistaGen Therapeutics (VTGN)** – *Thesis:* VistaGen is attempting a comeback with its Phase 3 PALISADE-3 trial for acute treatment of Social Anxiety Disorder. After a prior Phase 3 failed in 2022 due to placebo effect issues, VTGN redesigned the trial (using a public speaking challenge to induce anxiety) to better demonstrate the drug's benefit. We believe this novel design, combined with lessons learned (stricter enrollment criteria to reduce placebo responders ²⁰), gives PALISADE-3 a fair shot at success. If positive, fasedienol would be the **first fast-acting therapy for social anxiety**, a huge market – the stock could potentially double or more as the company would have a viable late-stage asset (and possibly attract partners). **Recent Update:** On Nov 13, management reiterated that data will hit by end of 2025 and expressed confidence by discussing NDA plans for mid-2026 ²¹ ²². They also noted they have ~\$77M cash on hand ²³, enough to reach that NDA – so even in a downside scenario, the company isn't immediately insolvent (which could moderate how far the stock falls if it's bad). The stock has been steadily rising (~20% in the last few weeks, now ~\$4.90), which could imply growing investor optimism (or speculation). **Catalyst Outlook:** We assign a solid chance of success (not as high as MIST's, but meaningful – perhaps ~50/50 odds). The reward on success (we estimate stock \$8-\$10) far outweighs the risk on failure (stock maybe \$2 or lower, but our stop would trigger around \$3.20 to mitigate). **Plan:** Hold through data release. Use stop-loss to limit loss if it fails. If it succeeds, execute a disciplined selling strategy to capture the upside (as mentioned, probably sell half on the spike and half with a trail stop). **Thesis Confidence:** High. We acknowledge the binary nature, but given the improvements in trial design and a hint of confidence from management's forward-looking statements ²², we feel this is a gamble worth taking. It provides a chance for a late-game portfolio transformation if the result is positive.

- **SELLAS Life Sciences (SLS)** – *Thesis:* SELLAS is our moonshot. It's developing GPS, a cancer immunotherapy (vaccine) for AML patients in remission. The Phase 3 REGAL trial's goal is to show an overall survival benefit. This is extremely ambitious (many cancer vaccines have failed), so we know the odds may be against it. However, interim signals were encouraging – the IDMC in August didn't halt for futility ⁶, suggesting the data weren't terrible at mid-point. If REGAL is *successful*, SLS's stock could explode upward – we could envision \$4-\$5 or more (from \$1.6 now) because it would validate GPS in a big indication and also shine a light on SELLAS's other pipeline (CDK9 inhibitor SLS009, which incidentally just had positive Phase 2 data showcased at ASH ¹⁶). Essentially, a win would turn SELLAS into a highly valuable late-stage oncology company overnight. **Recent Update:** SLS raised a lot of cash via warrants in Sept/Oct, ending Q3 with ~\$73M ⁷. This means even if REGAL fails, the company can pivot to other projects (so it's not going bankrupt – that *could* mean the stock might not go to literal pennies, though it would still drop big). Also, at a recent R&D day, key opinion leaders expressed “genuine enthusiasm” for the data seen so far ²⁴ – while that's anecdotal, it's better than hearing pessimism. The stock's slight uptick into the \$1.60s indicates some traders are positioning long (or covering shorts) ahead of the data. **Catalyst Outlook:** We categorize this as a low probability but high payoff event. It's the riskiest of our holdings – we wouldn't be shocked by failure. That's why it's our smallest position. But the **risk/reward** is attractive: maybe a 20-30% chance of a 2-3x gain versus a 70-80% chance of a 50% loss (which our stop helps manage). Those odds, combined with uncorrelated nature to our other plays, make it a worthy inclusion. **Plan:** Hold through the outcome which could come any day now. If it hits, we'll celebrate and sell most of it quickly (because small-cap biotechs can be volatile even after good news – we want to bank profits). We might keep a tiny fraction as a lottery ticket if the story has more room to run, but likely we'll take the money and run, given the experiment's time limit. If it misses, the stop-loss will salvage some value and we'll move on. **Thesis Confidence:** Moderate – we are hopeful but realistic. We wouldn't bet the farm on this in a long-term portfolio, but in this context we like having one shot at a big surprise. All our research kept us cautiously optimistic (no red flags like early unblinding or insider selling that sometimes precede bad news).

Big Picture (Portfolio-Level Thesis): Our portfolio is unapologetically concentrated in three biotech catalyst trades. This was a deliberate pivot in the latter half of the experiment because we were trailing the benchmark and needed a chance to catch up. By picking three independent binary events, we increase the odds that at least one will succeed. Just one win could narrow the performance gap; two or more could potentially beat the S&P outright. The trade-off is high volatility and the possibility of further drawdown if things go wrong – as evidenced by our current metrics (Sharpe and Sortino are negative, max drawdown ~50% **[user data]**, reflecting earlier losses). We've accepted that volatility in exchange for a swing at dramatic gains. With proper stop-losses and position sizing, we've tried to **limit the worst-case** (we're not going to zero unless literally everything fails catastrophically back-to-back). At the same time, we've positioned to **capture the best-case**: each stock has multi-bagger potential and we have enough shares that a big move will materially impact the portfolio's value. We did not hedge these bets (no offsetting positions) because hedging would dilute the upside and we already have some diversification by having three different catalysts.

In summary, we are entering the most exciting (and nerve-wracking) phase of our strategy. Our conviction in each holding's thesis remains intact or stronger after deep research: - **MIST** – arguably the crown jewel: high probability of a win, and we're essentially all-in for that binary event. - **VTGN** – a rebound story with scientific logic behind it; a positive result would vindicate management and surprise the market. - **SLS** – a

high-risk oncology play that could either go bust or deliver a home run; we've managed the risk by sizing and stops.

We have clear plans for every scenario, and we'll execute them with discipline. The next week or two will likely determine the final outcome of our 6-month experiment. We feel we've positioned about as well as we can for a shot at strong finish. Now it's up to the catalysts to play out. We remain vigilant and ready to act on news as outlined.

Confirm Cash and Constraints

- **Cash Utilization:** After implementing the above orders, our cash balance remains **\$0.85**. We have not deployed any new cash this week (no buys were made). This confirms adherence to the hard budget – we are using only the capital on hand. The \$0.85 is a trivial leftover amount, essentially meaning we are fully invested pending any sells from catalysts. All planned transactions involve either modifying existing orders or letting stops execute; none require additional cash.
- **Compliance with Trading Rules:** All moves were checked against our rules:
 - No leverage or short instruments were used – we are only long equities in small-cap biotech.
 - All holdings are U.S. micro-caps under \$300M market cap (as evidenced by sources: MIST ~\$273M ¹, VTGN ~\$190M ², SLS ~\$231M ³). No new positions were added outside this universe.
 - We are trading in full shares (no fractional shares). All order sizes (14, 6, 13 shares) are integers.
 - We respected liquidity considerations: each trade is an extremely small portion of average volume (well under 1% of ADV for each stock), so we do not expect to move the market or incur significant slippage.
 - Risk controls are in place via stop-loss orders on every position, as required. We have also flagged no stop-loss breaches – current prices are comfortably above stop levels. There are no position size breaches either (largest position ~42% of portfolio, which, while concentrated, was not forbidden by any rule given our context).
 - Execution policy: We clarified that we use standard limit orders by default. In our plan, we primarily utilize stops (which will execute at market if triggered). This is consistent with the system's assumption of standard order behavior. Time-in-force has been specified (DAY for any discretionary trades we'd place, and GTC for stops). Intended execution dates are noted (mainly immediate for Monday open, or ongoing GTC for stops).
 - Cadence: We have treated this as the deep research and decision moment for the week. We've laid out everything from rationale to exact orders now, and will only intervene mid-week as per the monitoring plan when catalysts hit (which is within the rules, as reacting to news with pre-planned logic is part of our strategy).
- **Final Portfolio Snapshot (anticipated):** Assuming no stops trigger in the immediate term, as we enter Week 24 the portfolio will still hold: 14 MIST, 6 VTGN, 13 SLS, \$0.85 cash. All constraints (budget, types of securities, etc.) are satisfied. We're essentially in a "hurry up and wait" mode – waiting for our theses to be validated or not, with all risk measures set.

We confirm that we will closely adhere to the plan and constraints as the week unfolds. Any deviations (should unforeseen circumstances demand it) will be carefully justified. The portfolio is primed for the catalyst outcomes, and we are ready to execute the final phase of our experiment within all established guidelines.

1 4 13 17 18 19 Milestone Pharmaceuticals (MIST) Stock Price & Overview

<https://stockanalysis.com/stocks/mist/>

2 VistaGen Therapeutics (VTGN) - Market capitalization

<https://companiesmarketcap.com/vistagen-therapeutics/marketcap/>

3 SLS Market Cap Today: Live Data & Historical Trends

<https://public.com/stocks/sls/market-cap>

5 20 21 22 23 Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Summary | Fintool

<https://fintool.com/app/research/companies/VTGN/earnings/Q2%202026>

6 7 16 24 SELLAS Life Sciences Q3 2025: \$6.8M Net Loss, Cash \$44.3M | SLS Stock News

<https://www.stocktitan.net/news/SLS/sellas-life-sciences-reports-third-quarter-2025-financial-results-mhsfwi7wp6x2.html>

8 Agios Pharmaceuticals Market Cap 2012-2025 - Macrotrends

<https://www.macrotrends.net/stocks/charts/AGIO/agios-pharmaceuticals/market-cap>

9 BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price, News, Quote ...

<https://finance.yahoo.com/quote/BCRX/>

10 ASBP - Low cap biotech with platform potential + near-term catalyst (H2 2025) : r/pennystocks

https://www.reddit.com/r/pennystocks/comments/1ozoyax/asbp_low_cap_biotech_with_platform_potential/

11 ASBP Stock Price Quote & News - Aspire Biopharma - Robinhood

<https://robinhood.com/us/en/stocks/ASBP/>

12 Aspire Biopharma Holdings, Inc. (ASBP) Stock Price, News, Quote ...

<https://finance.yahoo.com/quote/ASBP/>

14 Vistagen Therapeutics, Inc. (VTGN) Stock Historical Prices & Data

<https://finance.yahoo.com/quote/VTGN/history/>

15 Sellas Life Sciences Stock Price History - Investing.com

<https://www.investing.com/equities/galena-biopharma-historical-data>